FDA.reportPublic FDA data

selexipag 1.4 MG Oral Tablet [Uptravi]

RxCUI
1729033
RxNorm name
selexipag 1.4 MG Oral Tablet [Uptravi]
Display name
selexipag 1.4 MG Oral Tablet [Uptravi]
Full name
selexipag 1.4 MG Oral Tablet [Uptravi]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:13

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
UPTRAVISELEXIPAGActelion Pharmaceuticals US, Inc.a7a23b87-f892-4e2c-8e2e-ebf841220f902026-05-28Warnings, Adverse reactionsExact identifier
rxcui: 1729033

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a7a23b87-f892-4e2c-8e2e-ebf841220f90Uptravi 1400 MCG Oral Tablet [PSN] · selexipag 1.4 MG Oral Tablet [Uptravi] [SBD] · Uptravi 1.4 MG Oral Tablet [SY]326These highlights do not include all the information needed to use UPTRAVI safely and effectively. See full prescribing information for UPTRAVI. UPTRAVI ® (selexipag) tablets, for oral use UPTRAVI ® (selexipag) for injection, for intravenous use Initial U.S. Approval: 201520260528